| Literature DB >> 31853363 |
Nicolas Ansermot1, Meredith Bochatay2, Jürg Schläpfer3, Mehdi Gholam4, Ariane Gonthier5, Philippe Conus6, Chin B Eap2.
Abstract
BACKGROUND: Psychiatric patients are at risk of cardiovascular diseases, and many psychotropic drugs can prolong QTc interval. Requirements for electrocardiogram (ECG) monitoring have been set up in our psychiatric university hospital. The objective of this study was to determine the proportion of adult patients who had an ECG during their hospitalization, the prevalence of ECG abnormalities, the evolution of the QTc after admission, and the risk factors for QTc prolongation.Entities:
Keywords: QTc interval; electrocardiogram; psychiatric inpatients; psychotropic drugs
Year: 2019 PMID: 31853363 PMCID: PMC6909271 DOI: 10.1177/2045125319891386
Source DB: PubMed Journal: Ther Adv Psychopharmacol ISSN: 2045-1253
Classification of the 71 patients (17.9%) with at least one abnormal ECG, among the 396 patients with at least one valid ECG.
| Description | Number of patients (%)[ |
|---|---|
| Prolonged QTc (male: ⩾450 ms; female: ⩾460 ms) | 30 (7.6) |
| Repolarization abnormalities (excluding prolonged QTc and early repolarization) | 23 (5.8) |
| Atrioventricular conduction disturbances (PR <100 ms; PR > 200 ms) | 10 (2.5) |
| Intraventricular conduction disturbances (QRS >120 ms) | 5 (1.3) |
| Sinus bradycardia (<50 bpm) | 13 (3.3) |
| Sinus tachycardia (>120 bpm) | 2 (0.5) |
| Arrhythmias (premature beats; atrial fibrillation) | 10 (2.5) |
| Remote myocardial infarction | 3 (0.8) |
More than one type of ECG abnormality possible per patient.
bpm, beats per minute; ECG, electrocardiogram.
Figure 1.Flow chart for inclusion and exclusion of the ECGs in the various parts of the study.
ECG, electrocardiogram.
Figure 2.Distribution of the QTc values in the 595 valid ECGs.
ECG, electrocardiogram.
Description of the covariates included in the linear mixed-effects model (n = 357 ECGs).
| Covariates | Values |
|---|---|
| Females, | 149 (41.7) |
| Age (years), mean ± SD (range) | 39 ± 12 (18–64) |
| Potassium (mmol/l, ref. 3.5–4.6), mean ± SD (range) | 4.0 ± 0.4 (2.3–5.3) |
| Glucose (mmol/l, ref. 3.7–5.6), mean ± SD (range) | 5.1 ± 1.1 (2.5–12.9) |
| Triglycerides (mmol/l, ref. < 2.0), mean ± SD (range) | 1.3 ± 0.7 (0.4–7.8) |
| Cholesterol total (mmol/l, ref. < 5.0), mean ± SD (range) | 4.8 ± 1.1 (2.6–10.1) |
| Creatinine (µmol/l, ref. 62–106), mean ± SD (range) | 75 ± 19 (39–302) |
| At least one drug with known risk of TdP, | 102 (28.6) |
| At least one drug with possible risk of TdP, | 139 (38.9) |
| At least one drug with conditional risk of TdP, | 137 (38.4) |
| At least one strong CYP inhibitor, | 17 (4.8) |
| At least one strong CYP inducer, | 5 (1.4) |
| Time between admission and ECG (days), mean ± SD (range) | 5.4 ± 10.8 (0.02–87.7) |
| F10-F19 ICD diagnosis, | 106 (29.7) |
| QTc (ms), mean ± SD (range) | 418 ± 24 (352–487) |
Drugs classified according to their risk of TdP (www.crediblemeds.org):
Known risk: haloperidol (n = 38), escitalopram (n = 32), methadone (n = 19), citalopram (n = 15), levomepromazine (n = 6), domperidone (n = 2).
Possible risk: olanzapine (n = 40), risperidone (n = 29), mirtazapine (n = 25), aripiprazole (n = 20), venlafaxine (n = 19), clozapine (n = 10), lithium (n = 10), buprenorphine (n = 4), tizanidine (n = 2), paliperidone (n = 1), clomipramine (n = 1).
Conditional risk: quetiapine (n = 70), amisulpride (n = 33), sertraline (n = 18), trazodone (n = 12), fluoxetine (n = 6), hydroxyzine (n = 5), pantoprazole (n = 4), paroxetine (n = 3), indapamide (n = 2), amitriptyline (n = 1), hydrochlorothiazide (n = 1), metoclopramide (n = 1), ritonavir (n = 1).
Drugs classified according to their CYP inhibitor or inducer profile (www.pharmacoclin.ch):
Strong inhibitors: fluoxetine (n = 6), levomepromazine (n = 6), paroxetine (n = 3), darunavir (n = 1), fluvoxamine (n = 1), ritonavir (n = 1).
Strong inducers: oxcarbazepine (n = 2), dexamethasone (n = 1), phenobarbital (n = 1), ritonavir (n = 1).
CYP, cytochrome P450; ECG, electrocardiogram; F10-F19, ICD diagnosis: mental and behavioral disorders due to psychoactive substance use; SD, standard deviation; TdP, torsades de pointes.
Linear mixed-effects model (357 ECGs, 313 stays, 292 patients).
| Covariates | QTc | |
|---|---|---|
| Beta [ |
| |
|
|
|
|
|
|
|
|
| Potassium (mmol/l) | − 3.7 | 0.28 |
| Glucose (mmol/l) | + 1.3 | 0.26 |
|
|
|
|
| Cholesterol total (mmol/l) | − 1.6 | 0.22 |
| Creatinine (µmol/l) | + 0.006 | 0.93 |
|
|
|
|
| At least one drug with possible risk of TdP [ | + 3.6 | 0.13 |
| At least one drug with conditional risk of TdP [ | + 3.6 | 0.14 |
| At least one strong CYP inhibitor [ | + 6.4 | 0.21 |
| At least one strong CYP inducer [ | − 0.01 | 0.99 |
| Time between admission and ECG (days) | − 0.1 | 0.54 |
| F10-F19 ICD diagnosis | + 0.5 | 0.87 |
Effect of the covariate on the QTc.
Based on the classification of CredibleMeds (www.crediblemeds.org).
Based on the classification of the Geneva University Hospitals (www.pharmacoclin.ch).
CYP, cytochrome P450; ECG, electrocardiogram; F10-F19, ICD diagnosis: mental and behavioral disorders due to psychoactive substance use; TdP, torsades de pointes.